The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb ...

The Food and Drug Administration approved Cobenfy, a twice-a-day medication that is a new kind of treatment for schizophrenia in adults. Steve Belkowitz/Bristol Myers Squibb hide caption ...

People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug.. Studies ...

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.

The U.S. Food and Drug Administration late Thursday approved a new kind of drug to treat schizophrenia, a breakthrough after 70 years of incremental innovation that appears to avoid side effects ...

After decades of antipsychotic drugs, a new FDA-approved treatment for schizophrenia targets a different brain system—with ...

The elimination of 3,500 full-time employees at the FDA risks undermining the very innovation and domestic capacity the ...

The technology behind the weekly pill is as much mechanical as it is pharmaceutical. Encased in a standard-size capsule is a ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for milsaperidone (Bysanti ™) for the treatment of acute bipolar I disorder and schizophrenia.

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, combines ...